Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Q3 2018 · 10-Q
Revenue$1.57M$1.57M+22.7% vs Q3 2017 Net Income-$1.33M-$1.33MN/M vs Q3 2017 EPS Diluted-$0.02-$0.02N/M vs Q3 2017 Gross Profit$609,000+107.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,080,000N/M Free Cash Flowderived-$1,161,000N/M Margins · derivedGross margin38.7%+15.9 pt vs Q3 2017
Operating margin-85.1%+23.2 pt vs Q3 2017
Net margin-84.7%+21.4 pt vs Q3 2017
ended Mar 31, 2018 · filed May 4, 2018 · 34 d after period end